Cullinan Therapeutics, Inc.
cullinantherapeutics.comWhat Do They Do?
Develops experimental T cell-engaging therapies for autoimmune diseases and cancer, along with a targeted lung cancer drug, for patients with autoimmune conditions and blood and lung cancers.
10-K for FY2025, filed Mar 10, 2026We are a biopharmaceutical company developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer.…View ↗
CLN-978 is a CD19xCD3 bispecific T cell engager that we are developing for autoimmune diseases. In the Phase 1 OUTRACE Program, CLN-978 is…View ↗
CLN-049 is a FLT3xCD3 bispecific T cell engager. CLN-049 is being evaluated in an ongoing Phase 1 clinical trial in patients with…View ↗
Zipalertinib (CLN-081/TAS6417), on which we are collaborating with an affiliate of Taiho Pharmaceutical Co., Ltd. ("Taiho"), is an…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$53.7MView ↗
- ▼ −23% (Loss)
- vs −$70.1M in Q2 FY2025
-
Sep 13, 2026
Zipalertinib plus chemotherapy improved progression-free survival versus chemotherapy alone
Median progression-free survival was 14.5 months versus 8.5 months with chemotherapy alone.
Sources
8-K, filed Sep 14, 2026
At the pre-planned interim efficacy analysis after 122 progression free survival ("PFS") events, treatment with zipalertinib plus…View ↗
-
Aug 13, 2026
Zipalertinib combination met the trial’s primary endpoint
The company and Taiho said they plan to pursue U.S. regulatory approval for the first-line combination, pending discussions with the FDA.
Sources
8-K, filed Aug 13, 2026
On August 12, 2026, the Company and Taiho announced that the REZILIENT3 clinical trial met its primary endpoint of PFS at a planned interim…View ↗
Expanded into immunology
The older report described a targeted oncology-focused pipeline. The latest report also describes programs for autoimmune diseases alongside its cancer therapies.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Mar 10, 2026We are a clinical-stage biopharmaceutical company focused on modality-agnostic targeted oncology. Our strategy is to identify high-impact…View ↗
We are a biopharmaceutical company developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer.…View ↗
Who Do They Compete With?
Competes with Amgen, Roche Holdings, AstraZeneca, Merck &, Novartis, GSK, Xencor, Zenas BioPharma, Eli Lilly and, Climb Bio, Regeneron Pharmaceuticals, Candid Therapeutics, Ouro Medicines, Astellas Pharma, Daiichi Sankyo, Aptose Biosciences, Veraxa Biotech, Hemogenyx Pharmaceuticals, Senti Biosciences, and Johnson & Johnson
10-K for FY2025, filed Mar 10, 2026With respect to our CLN-978 program, we are aware of multiple companies with development-stage CD19 T cell engager programs for the…View ↗
Loading...
